The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.
Clinical trial NCT04777084 · RECRUITING
Trial details
- NCT number
- NCT04777084
- Sponsor
- Hunan Province Tumor Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-01
- Primary completion
- 2024-12-30
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.